Top Story

FDA restructures, renames office that reviews cancer therapies

FDA restructures, renames office that reviews cancer therapies
November 6, 2019
Trend Watch

MD Anderson, Ziopharm renew R&D agreement to include T-cell receptor-based therapies

October 31, 2019
The University of Texas MD Anderson Cancer Center has announced a new research and development agreement with partner Ziopharm Oncology for the development of…

ASH elects three to leadership positions

October 31, 2019
ASH announced the election of three clinicians to leadership positions within the society. Jane Winter, MD, will serve a 1-year term as vice president, followed…
In the Journals

Gilteritinib new standard of care for relapsed, refractory FLT3-mutated acute myeloid leukemia

October 30, 2019
Gilteritinib significantly extended OS and demonstrated higher rates of complete response compared with standard salvage chemotherapy among patients with relapsed or…
More Headlines »

Acute Lymphoblastic Leukemia Posters and Abstracts from San Diego

This activity is supported by educational funding provided by Amgen.

In this CME activity Elias Jabbour, MD, provides his perspectives on key posters presented at the American Society of…
More »
Meeting News

VIDEO: Initial results of ZUMA-3 trial ‘highly encouraging’ for relapsed, refractory leukemia

July 21, 2019
More »
Resource Centers
Discoveries from ASH Leukemia

Discoveries from ASH Leukemia


Focus on Advancing Treatment for Acute Myeloid Leukemia

This activity is supported by an independent educational grant from Pfizer, Inc.

In this activity, Bruno Medieros, MD, and Farhad Ravandi-Kashini, MD, discuss recent advances in the treatment of acute…
More »